The introduction of the Novavax vaccine, also referred to as Nuvaxovid, which provides a protein-based substitute for mRNA vaccinations, marked a key evolution in Australia’s COVID-19 immunization program. Those who are wary of modern vaccine technology have found this alternative very tempting.
What Is the Novavax Vaccine?
Nuvaxovid is a recombinant protein vaccine developed by Novavax Inc., utilizing a laboratory-produced version of the SARS-CoV-2 spike protein, combined with the Matrix-M adjuvant to enhance the immune response. Unlike mRNA vaccines, Nuvaxovid contains purified protein antigen and cannot replicate or cause COVID-19. Novavax Investor Relations | Novavax+2Health.gov.au+2Health.gov.au+2Novavax Investor Relations | Novavax
Approval Timeline in Australia
- January 2022: The Therapeutic Goods Administration (TGA) provisionally approved Nuvaxovid for adults aged 18 and over. Health.gov.au
- June 2022: The TGA extended approval for Nuvaxovid to be used as a booster dose in adults. RACGP+10Novavax Investor Relations | Novavax+10Novavax Investor Relations | Novavax+10
- July 2022: Provisional approval was granted for adolescents aged 12–17 years, following positive results from clinical trials. Therapeutic Goods Administration (TGA)+3Health.gov.au+3Therapeutic Goods Administration (TGA)+3
Who Can Receive Novavax?
The Australian Technical Advisory Group on Immunisation (ATAGI) recommends Nuvaxovid for:Therapeutic Goods Administration (TGA)+3Health.gov.au+3Health.gov.au+3
- Primary vaccination: Individuals aged 12 and over, administered as two doses at least three weeks apart.Therapeutic Goods Administration (TGA)+1Health.gov.au+1
- Booster doses: Adults aged 18 and over, particularly when mRNA vaccines are unsuitable. Health.gov.au
For adolescents, an extended interval of eight weeks between doses is advised to potentially enhance effectiveness and reduce the risk of myocarditis. Health.gov.au
Use in Special Populations
While data on the use of Novavax in pregnant and breastfeeding women are limited, ATAGI notes no theoretical safety concerns, as Nuvaxovid is not a live vaccine. It can also be administered to individuals with prior SARS-CoV-2 infection and those with severe immunocompromise. Novavax Investor Relations | Novavax+5Health.gov.au+5RACGP+5
Supply and Distribution
In January 2021, the Australian Government secured 51 million doses of Nuvaxovid through an agreement with Novavax. The vaccine is available through various channels, including general practices and pharmacies.